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Objectives: We conducted a systematic meta-analysis to evaluate the incidence, temporal trends and potential risk 
factors for prosthetic joint infection (PJI) following primary total shoulder replacement (TSR) and elbow replacement 
(TER). 
Methods: Longitudinal studies reporting infection outcomes following primary TSR or TER were sought from 
MEDLINE, Embase and Cochrane Library up to June 2019. Incidence rates and relative risks (with 95% CIs) were 
calculated.  
Results: The search identified 105 eligible articles (108 non-overlapping studies). There were 631,854 TSRs (1,751 
PJIs) and 17,485 TERs (525 PJIs). The pooled PJI incidence following TSR was 0.61% (0.34-0.93) over a follow-up 
period of 1.1 years. The corresponding incidence following TER was 2.53% (1.99-3.12) over a follow-up period of 3.3 
years. Shoulder and elbow PJI incidence declined from the 1990s to 2010 and beyond. Males, younger age (<75 
years), previous shoulder surgery, reverse TSR, rotator cuff arthropathy and inpatient TSR increased shoulder PJI risk. 
For TER, high body mass index, psychiatric illness, and previous elbow surgery increased PJI risk. 
Conclusions: Shoulder and elbow PJI may be on a temporal decline. Caution should be taken for patients at high PJI 
risk following primary TSR such as younger males and patients with a previous shoulder surgery. 
 
Systematic review registration: PROSPERO 2019: CRD42019139100 
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Prosthetic joint infection (PJI) is a potentially devastating, albeit uncommon complication of total joint replacement 
(TJR) which often results in the need for implant revision.(1, 2) Prosthetic joint infection carries a substantial public 
health burden; being an important cause of reduced quality of life in affected patients,(3-5) high healthcare costs(6) 
and even death if left untreated.(7) Though PJI can occur in any joint following TJR, much of the literature on the 
incidence, risk factors, diagnosis, prevention, and treatment of PJI following TJR is based on lower extremity joints 
(hip and knee joints). This is because hip and knee replacement are more common than shoulder and elbow 
replacements. In England and Wales in 2017, approximately 100,000 joint replacements were performed each in knees 
and hips; whereas only approximately 7,000 shoulder and 600 elbow replacements were performed, as recorded in the 
largest mandated national arthroplasty registry – the National Joint Registry for England, Wales and Northern Ireland 
and the Isle of Man.(8) Though it has been reported that PJI of the shoulder is less frequent compared to PJI of the 
knee and hip(9) and affects about 1% of patients,(10) treatment of shoulder PJI is more challenging(11, 12)  and 
associated with higher morbidity and costs compared with PJIs of other joints.(13, 14) Compared with hip or knee 
replacement, there is a higher incidence of PJI following total elbow replacement (TER) which has been reported to 
range between 1-19%.(15-18) 
 
Given that only relatively few shoulders and elbows are replaced each year, the literature is sparse on incidence rates 
for PJI and potential factors that influence the risk of PJI for these joints. The reported incidence rates in the literature 
have been based on small case series and are highly variable. Though there is established evidence that several patient-
, surgery-, and hospital-related factors are associated with the risk of PJI following total hip and knee replacement,(19-
21) it is uncertain if these potential risk factors also influence PJI risk following total shoulder and elbow replacement 
in a similar way. Furthermore, different risk factors may be related to different bacterial profiles for PJI in different 
joints. For example, though the most commonly identified microorganisms in PJI of the shoulder are Cutibacterium 
acnes, Staphylococcus aureus, and coagulase-negative Staphylococcus aureus, indolent bacteria such as 
Cutibacterium acnes are predominant in shoulder PJIs and are hardly seen in PJIs of the hips and knees.(22) Amongst 
all orthopaedic joint replacements, the numbers of shoulder and elbow joint replacements are increasing most rapidly; 
in the United States, the number of shoulder replacements increased from 28,000 per year between 2000 and 2008 to 
about 100,000 in 2015.(23)  It is expected there will be a seven-fold increase in demand of shoulder replacements over 




of PJI, temporal changes in the incidence of PJI are expected. Hence, there is a need for robust aggregation of data on 
PJI incidence and its temporal trends as well as identification of potential risk factors for the development of PJI 
following upper extremity joint replacement. This data will be of great value for policy makers, healthcare systems 
and clinicians to aid in planning and implementing more efficacious preventative strategies. In this context, using a 
systematic review and meta-analysis, we aimed to (i) pool incidence of PJI following primary total shoulder 
replacement (TSR) and TER and characterise their temporal trends; (ii) quantify the nature and magnitude of 
associations of potential patient-, surgery-, and hospital-related factors with the risk of PJI following primary TSR and 
TER; and (iii) to identify potential gaps in the existing literature. 
 
Methods 
Data sources and search strategy 
This review conducted according to a pre-defined protocol and PRISMA and MOOSE guidelines(25, 26) 
(Supplementary Materials 1-2) was registered with the prospective register of systematic reviews, PROSPERO 
(CRD42019139100). An electronic search of MEDLINE, Embase and Cochrane databases was performed from 
inception to 20 June 2019 for studies reporting on PJI outcomes following TSR or TER. The computer-based searches 
used free and MeSH search terms and combination of key words related to the population (e.g., “total shoulder 
replacement”, “total elbow replacement”) and outcome (e.g., “prosthetic joint infection”, “deep infection”) with no 
language restrictions (Supplementary Material 3). Following retrieval of potential studies, the titles and abstracts 
were initially screened to assess their suitability for inclusion, after which full texts of potentially relevant studies were 
acquired for more detailed evaluation. The evaluation was conducted independently by two experienced reviewers 
(SKK and MCB) and where there were disagreements regarding eligibility of an article, this was discussed with a third 
reviewer (MRW) to reach consensus. Reference lists of relevant studies and reviews were reviewed manually to check 
for potential eligible studies missed by the search strategy. 
 
Eligibility criteria 
All longitudinal studies (prospective or retrospective cohorts, nested case-controls, case-cohorts, case series, or 
clinical trials) were included in the review if they recruited patients who had undergone elective primary TSR 
(anatomic TSR or reverse TSR) or TER, reported on outcomes of PJI following the surgery and/or reported on the 




or past medical and/or surgical history), surgery-related factors (e.g., procedure type or use of bone cement), or 
hospital-related factors (such as hospital volume or surgeon experience). Studies that included both elective and 
trauma indications for surgery or included both total and partial (e.g. hemiarthroplasty) joint replacements were 
considered and included if they contained large mixed samples. The primary outcome was PJI (which included deep 
infection, deep surgical site infection, or deep prosthetic infection), with superficial wound infection being a 
secondary outcome. The following studies were excluded: (i) comprising revision total shoulder or elbow joint 
replacements or a mixture of primary and revision joint replacements from which data could not be extracted on 
primary joint replacements; (ii) comprising of selected populations or patients with prevalent conditions (e.g. diabetes, 
haemophilia, etc.) or selected populations with no comparison or control groups; (iii) assessed exposures (conditions) 
that developed after the joint replacement; and (iv) that exclusively focused on any other surgical approach apart from 
total elbow or shoulder replacement such as in the setting of trauma, non-union, fracture, bilateral arthroplasty, 
arthroscopy or hemiarthroplasty.  
 
Data extraction and quality assessment 
Data was initially extracted by one experienced reviewer (SKK) using a standardized data collection form which has 
been pre-tested and employed in several previous reviews of a similar nature.(19, 27) The second reviewer (MCB) 
independently checked the extracted data with that in original articles and any disagreements were discussed with the 
third reviewer (MRW) to reach a consensus. Data was extracted on study level characteristics, type of joint, sample 
size, type of and counts for outcomes, risk estimates for outcomes (relative risks (RRs), hazard ratios (HRs), or odds 
ratios (ORs)) and degree of adjustment for potential confounders (univariable or multivariable). When there were 
multiple publications involving the same study or cohort, we extracted the most comprehensive up-to-date single set 
of results to avoid double counting in our analyses. We contacted study investigators to provide additional data where 
necessary. The methodological quality of each study was assessed using the nine-star Newcastle-Ottawa Scale (NOS) 
validated for assessing the quality of non-randomised studies(28) and uses three pre-defined domains including: (i) 
selection of participants; (ii) comparability; and (iii) ascertainment of outcomes of interest. Nine points on the NOS 
reflects the highest study quality. 
 




In pooling PJI incidence across studies, the incidence (estimated from the number of PJI outcomes within period of 
follow-up/total number of participants or procedures as reported) with 95% confidence intervals (CIs) was used as the 
summary measure. Given that the data was binary with low rates, the Freeman-Tukey variance stabilising double 
arcsine transformation (29) was used in calculating the rates as done in previous reports.(30-32) Temporal trends in 
incidence were evaluated using the median year of data collection/surgery reported by studies, as previously 
reported.(33) The measures of association were presented as RRs with 95% CIs. Following Cornfield’s rare disease 
assumption(34), HRs and ORs were assumed to approximate the same measure of RR. Multivariable-adjusted risk 
estimates were used for pooling when reported, otherwise crude RRs were calculated from studies that provided raw 
counts. Different BMI cut-offs were reported by the eligible studies, hence to ensure consistency in the pooling 
approach and enhance comparability and interpretation of findings, we employed the following risk comparisons 
based on the data available and to maintain consistency with previous reports: ≥25 vs. <25, ≥30 vs. <30, ≥40 vs. <40 
kg/m2 and per unit increase in BMI.(19, 27) Random-effects models by DerSimonian and Laird which takes into 
account heterogeneity both within and between studies, were used to combine RRs and account for the effect of 
heterogeneity.(35) In the absence of substantial heterogeneity, fixed-effect models were employed.  We estimated 
95% prediction intervals to determine the degree of heterogeneity, as they provide a range in which the underlying 
true effects of future studies will lie with 95% certainty.(36, 37) We conducted stratified analyses and random effects 
meta-regression to assess several pre-defined study level characteristics which could explain heterogeneity between 
the studies.(38) All statistical analyses were conducted using STATA SE 15.1 (Stata Corp, College Station, Texas, 
USA).   
 
Results 
Study identification and selection 
The study selection progress is summarised in Fig. 1. A total of 244 potential citations were identified after the 
literature search and manual screening of relevant articles. Of these, 153 seemed to satisfy the review inclusion criteria 
based on titles and abstracts. Following detailed evaluation of full texts, 48 citations were excluded due to the 
following reasons: (i) population was not relevant (n=21); (ii) duplicate of another study included in review (n=14); 
(iii) the outcome was not relevant (n=9); (iv)) study design was not relevant (n=3); and (v) full text not accessible 
(n=1). The remaining 105 citations which comprised of 108 non-overlapping studies were eligible to be included in 





Study characteristics and study quality 
The 108 distinct studies comprised of 24 studies of TSRs and 84 of TERs. Publication dates of included studies ranged 
from 1989 to 2019. Table 1 is a summary table of relevant study characteristics for both types of joint replacements. 
Supplementary Material 5 provides details of the key characteristics and quality assessment scores of the individual 
studies. Overall, there were 631,854 TSRs and 1,751 PJIs; the corresponding figures for TERs were 17,485 and 525 
respectively.  
Patient populations were recruited from North America (Canada and USA), Europe (Belgium, Czech, Denmark, 
Finland, France, Germany, Italy, The Netherlands, Norway, Switzerland, Spain and Sweden, UK), Asia (China, Korea 
and Japan) and the Pacific (Australia). For TSRs, the weighted mean age and mean follow-up duration was 68.8 and 
1.3 years respectively and that for TERs was 59.5 and 3.3 years respectively. Prosthetic joint infection outcomes were 
reported in a variety of ways which included infection, deep infection, surgical site infection, and revision for 
infection (Supplementary Material 5). Registry studies reported this outcome as revision due to infection, which was 
defined as removal or exchange of the whole or part of the prosthesis with infection reported as the cause of revision. 
The majority of studies did not provide details on the definition of infection or its diagnosis. However, a few studies 
defined PJI based on findings by the surgeon at preoperative assessment and during surgery. The majority of studies 
did not provide information on bacterial profiles responsible for infection; however, for the few studies that reported 
these data, the most predominant bacteria were Cutibacterium acnes and Staphylococcus aureus (Supplementary 
Material 5). Methodological quality of all included studies ranged from 6-9.   
 
Incidence of infection following primary TSR 
Across 22 studies of TSR with relevant data, the incidence of PJI over a weighted mean follow-up duration of 1.1 
years ranged from 0.00% to 4.56%. The pooled random effects incidence (95% CI) over this follow-up duration was 
0.61% (0.34-0.93) (Fig. 2). The 95% prediction interval for the summary incidence was 0.00 to 2.32%, suggesting that 
the true incidence for any single new study will usually fall within this range. The pooled incidence of superficial 
wound infection of three studies over a weighted mean follow-up duration of 7.4 years was 0.08% (0.00-0.42). 
Comparing PJI outcome by TSR procedure type, the PJI incidence for anatomic TSR was 0.48% (0.28-0.73) over a 
weighted mean follow-up duration of 2.4 years and that for reverse TSR was 0.78% (0.06-2.02) over a weighted mean 




average follow-up periods reported by studies was 0.10% (0.07-0.14) at < 30 days, 0.34% (0.11-0.67) at 30 days, 
0.16% (0.12-0.22) at 60 days, 0.34% (0.12-0.64) at 3 months, 0.59% (0.49-0.72) at 6 months, 0.39% (0.03-0.99) at 1 
year, 1.29% (0.72-2.01) at 2 years, 1.18% (0.37-2.32) at 3 years, 1.21 (0.88-1.58) at 5 years, 1.05% (0.79-1.39) at 10 
years, and 1.51% (1.22-1.87) at 15 years  (Supplementary Material 7). Based on the median year of data 
collection/surgery, the pooled incidence of PJI was 1.51% (1.22-1.87) in the 1990s, 0.61% (0.26-1.07) in 2000-2009 
and 0.63% (0.22-1.18) in 2010 and beyond (Fig. 3A). In meta-regression analysis, there was no significant association 
between PJI incidence and median year of data collection/surgery (p=0.801) (Fig. 3B). 
 
Incidence of infection following primary TER 
Across 82 studies of TER with relevant data, PJI incidence over a weighted mean follow-up duration of 3.3 years 
ranged from 0.00% to 11.76%. The pooled random effects incidence (95% CI) over this follow-up period was 2.53% 
(1.99-3.12) (Fig. 4). In pooled analysis of 11 studies, the incidence of superficial wound infection over a weighted 
mean follow-up duration of 9.4 years was 1.45% (0.19-3.44). Comparing PJI outcome by type of elbow prosthesis 
(linked vs. unlinked), the PJI incidence for linked elbow prosthesis was 2.35% (1.55-3.28) over a weighted mean 
follow-up duration of 6.2 years and that for unlinked prosthesis was 2.01% (1.39-2.72) over a weighted mean follow-
up duration of 8.8 years (Supplementary Material 8). The pooled incidence of PJI at specific average follow-up 
periods reported by studies was 1.59% (0.54-4.56) at 30 days, 2.67% (2.10-3.31) at 90 days, 2.00% (0.35-10.50) at 1 
year, 5.89% (1.56-12.03) at 2 years, 1.86% (0.91-3.04) at 3 years, 3.22 (2.22-4.35) at 5 years, 1.49% (0.61-2.64) at 10 
years, and 0.50% (0.00-3.00) at 15 years  (Supplementary Material 9). There seemed to be a temporal decline in PJI 
incidence from the 1980s to 2010 and beyond based on median year of data collection (Fig. 3C), but the decline was 
not statistically significant in a meta-regression analysis (p=0.683) (Fig. 3D). 
 
Potential risk factors for PJI following primary TSR 
The associations of sociodemographic, BMI comparisons, medical and surgical history characteristics with the risk of 
PJI following TSR are summarised in Fig. 5. Older age was associated with a decreased risk of PJI: RRs (95% CIs) of 
0.62 (0.48-0.79) and 0.95 (0.92-0.98) comparing age ≥75 years vs. <75 years and per one-year increase respectively. 
Comparing males with females in three studies, the pooled RR (95% CI) for PJI was 1.95 (1.52-2.48) (Fig. 5). There 
was no strong evidence of associations of other sociodemographic characteristics such as race and smoking status with 




marginally significant increase in PJI risk comparing BMI ≥30 vs. <30 kg/m2 RR (95% CI) of 1.60 (0.99-2.56). A 
history of sleep apnoea and previous shoulder surgery were each associated with an increased risk of PJI, RRs (95% 
CIs) of 1.33 (1.15-1.54) and 1.92 (1.14-3.23) respectively. In evaluation of surgical indications for TSR, neither 
rheumatoid arthritis nor inflammatory arthritis was associated with PJI risk; however, rotator cuff arthropathy was 
associated with an increased risk of PJI when compared with osteoarthritis, RR (95% CI) of 3.13 (2.01-4.87) (Fig. 5). 
The associations of surgery- and hospital-related factors with risk of PJI following TSR are summarised in Fig. 6. 
Comparing reverse TSR vs. anatomic TSR and outpatient TSR vs inpatient TSR, RRs (95% CIs) were 2.19 (1.66-
2.89) and 0.38 (0.21-0.69) respectively. Other factors such as implant fixation, surgeon experience and period or 
seasonality of surgery were not found to be associated with PJI risk following TSR (Fig. 6). In a retrospective study 
that compared an innovative supplemental UV-C air decontamination technology plus standard HEPA-filtered HVAC 
versus standard HEPA-filtered HVAC for the incidence of PJI following TSR, no cases of PJI occurred in either group 
after 12 months of follow-up.(39) 
 
Potential risk factors for PJI following primary TER 
Only two studies were identified to have quantitatively assessed potential risk factors for PJI following primary TER. 
The RR (95% CI) for PJI comparing BMI ≥30 vs <30 and ≥40 vs <40 kg/m2 was 2.20 (1.60-3.10) and 2.50 (1.89-3.29) 
respectively (Supplementary Material 10). A history of psychiatric illness and a previous elbow surgery were each 




Over a weighted average follow-up period of about a year, the incidence rates for PJI following primary TSR ranged 
from 0.00 to 4.56% across individual studies and averaged approximately 0.61% in pooled analysis. The PJI incidence 
was higher following reverse TSR compared with anatomic TSR. For TER, the PJI incidence rate ranged from 0.00% 
to 11.76% across individual studies and averaged 2.53% over an average follow-up period of approximately 3 years. 
The PJI incidence rates for linked and unlinked elbow prosthesis were similar, ranging from 2.01% to 2.35%. For both 
shoulder and elbow joints, the risk of PJI is not constant in the post-operative period but appears to be higher at 2 
years postoperative. There appeared to be a temporal decline in both shoulder and elbow PJI rates from the 




associations with the risk of PJI following TSR, younger patients, males, and patients with a previous shoulder 
surgery, each had an increased risk of PJI. The increased PJI risk associated with younger patients is unclear,(40) but 
that in males has been attributed to a higher bacterial load of Cutibacterium acnes.(41) The findings in males may 
reflect the observation that Cutibacterium acnes was the predominant bacteria in one of the studies contributing to the 
pooled analysis.(41) The finding of an increased risk of PJI associated with rotator cuff arthropathy compared to 
osteoarthritis probably reflects less protection of the implant by vascularised tissue, hence more haematoma formation 
which increases the risk of infection;(42) on the other hand, this finding may reflect the use of reverse TSR in treating 
rotator cuff arthropathy rather than the surgical indication itself. Compared to anatomic TSR, reverse TSR is 
commonly used in treating rotator cuff arthropathy(43) and is also associated with higher incidence of PJIs as 
confirmed in our aggregate review. Patients with a history of sleep apnoea also had an increased risk of PJI. Sleep 
apnoea might be a surrogate measure for obesity, smoking, or cardiopulmonary complications,(44, 45) which are 
factors known to increase the risk of PJI in hip and knee joints.(19-21) In the current study, obesity was potentially 
associated with an increased risk of PJI following TSR, but the result was marginally significant. Compared to 
inpatient TSR, outpatient TSR was associated with a reduced risk of PJI, which likely reflects a patient selection 
effect. For TER, high BMI, psychiatric illness, and previous elbow surgery increased the risk of PJI. 
 
Comparison with previous work 
A number of previous reviews have attempted to synthesise the evidence on incidence rates of PJI following TER, but 
these reports have either been based on few studies or did not employ meta-analytic approaches to summarise the 
evidence. Voloshin and colleagues reported the deep infection rate to be 3.3%.(46) Welsink and colleagues recently 
reviewed 73 articles comprising a total of 9,379 TERs in an attempt to summarise survival rates, functional results and 
complication rates of TER implants.(47) The authors reported a deep infection rate of 3.4% (207 of 6,091 TERs). van 
der Lugt and colleagues have also reported infection rates ranging from 0.7% to 4.0% according to the type of elbow 
prosthesis used.(48) Though these previous reports provide relevant findings, a major limitation in their approach was 
that incidence rates were estimated from the number of infections divided by the total number of joint procedures and 
expressed as a percentage; hence, such findings do not account for time. By employing relevant statistical approaches 
and taking into account the period of follow-up (weighted means), our review represents the first attempt at evaluating 
and synthesising overall PJI incidence rates, period-specific PJI risk and its temporal trends. We did not identify any 




this is the first aggregate analysis to evaluate the associations of patient-, surgery-, and hospital-related factors with 
PJI risk following TSR. The current review has also identified large gaps in the existing literature – though TERs are 
associated with higher incidence of PJIs compared with hip, knee or shoulder replacements,(15-17) only a few studies 
have evaluated  the role of potential risk factors for PJI development in these joint and this may reflect the fact that 
relatively few elbow replacements are performed compared to shoulders, hips or knees.(8) Furthermore, existing cases 
series are small and have low event rates, hence do not have adequate power to investigate potential associations. 
 
Implications of our findings  
With increase in life expectancy and a growing burden due to degenerative conditions such as rotator cuff arthropathy 
and osteoarthritis, there will be an increase in demand for joint replacements. Though relatively few total shoulder and 
elbow replacements are performed compared with hip or knee replacements,(8) recent data suggests that there will be 
a sharp increase in demand for TSRs over the next decade.(24) The temporal decline in the incidence of PJI suggested 
by our findings is not unexpected and this likely reflects innovations in surgical procedures and behaviour, as well as 
antibiotic prophylaxis. However, with the increase in demand for shoulder replacements especially, it is likely there 
will be a proportionate rise in the overall burden of PJIs. The social, health and economic costs associated with 
shoulder and elbow PJI and its treatment are substantial and potentially devastating.(22, 49-51) Our data on the 
incidence rates and temporal trends of PJI is a valuable data resource for clinicians and policy makers, as it enables 
quantification of the societal impact of PJIs and assists in planning purposes. The high PJI rates following TSR and 
TER at 2 years postoperative compared to the immediate postoperative period, suggests that patients should have at 
least a minimum follow-up of 2 years following primary surgery. We have also shown that the aetiology of PJI 
following TSR is multifactorial and is influenced by several modifiable factors which can be optimised prior to joint 
surgery. Recognition of unmodifiable factors such as younger age and male sex could be used to counsel patients 
regarding their individual risk for PJI when undergoing joint replacement. In cases where it is felt that there is a high 
risk of needing to carry out a joint replacement in the near future, patients may prefer to avoid other, temporising 
surgical procedures that would lead to an increase in their risk of subsequent PJI. Finally, our findings provide insight 
on the large gaps in the existing literature regarding definitive evidence on the role of potential risk factors for PJI 
following total shoulder and elbow replacements. Investigators of case series on these upper extremity joint 





Study strengths and limitations 
To our knowledge, this is the first aggregate analysis to assess the overall and period-specific incidence of and 
temporal trends in PJI following primary total shoulder and elbow replacement and evaluate the associations of 
patient-, surgery-, and hospital-related factors with PJI risk in one single comprehensive investigation. Appropriate 
meta-analytic approaches were utilised in all analyses and which included accounting for heterogeneity between 
contributing studies and ensuring that studies with zero rates were not excluded from the pooled analysis as well as the 
use of meta-regression techniques. We conducted quality assessments using a validated tool and employed 
comprehensive data checks to ensure that participants were not double during pooling, given that some of the articles 
were based on the same database or study. There were a number of limitations: (i) there was absence of clear 
definitions for PJI in the majority of studies and these were reported in a variety of ways for studies that reported these 
data; we acknowledge that this did not enhance consistency of the pooling approach and could have limited the 
validity of the findings. In addition, a number of registry studies were included in our analyses and these are known to 
under-report revision for PJI and thus their incidence estimates of PJI are potentially lower;(52) (ii) furthermore, 
incidence rates for PJI following TSR may be underestimates, given that PJI in the shoulder is difficult to diagnose 
especially when associated with low virulence infections caused by Cutibacterium acnes;(22) (iii) it is acknowledged 
that the associations could be influenced by the particular prevalence of bacteria associated with PJI in the data used; 
however, we were unable to explore this because majority of studies did not provide profiles of the bacteria causing 
PHI; (iv) though an eligibility criterion was to include only studies that recruited patients who had undergone elective 
TJR, a number of studies included a mix of elective and trauma indications for TJR, hemiarthroplasties, and 
resurfacing arthroplasties whose data could not be disentangled, hence the effect estimates may be biased; (v) the 
majority of studies did not adjust for confounding and for those that adjusted for confounding, there was a potential 
for residual confounding; (vi) findings on the temporal trends in PJI rates were based on median year of data 
collection reported by studies, which may not accurately capture specific periods of surgery and follow-up; and (vii) 
several of the findings on risk factor evaluations were based on single study reports with imprecise estimates, hence 
need interpretation with caution. 
 
Conclusions 
Over an average period of 1 year, the average incidence of PJI following TSR is less than 1%. Following TER, the 




and TER is higher at 2 years postoperative compared to the immediate postoperative period. There appears to be a 
temporal decline in PJI rates following both primary total shoulder and joint replacements from the 1980s/1990s 
through to 2010 and beyond, though the evidence is not robust. The risk of PJI following primary TSR has a 
multifactorial aetiology and is influenced by a number of patient-, surgery-, and hospital-related factors. Particular 
caution should be taken for patients at high risk of PJI following primary TSR such as younger males and patients 
with a previous shoulder surgery or rotator cuff arthropathy and they should be counselled accordingly. 
 




This article presents independent research funded by the National Institute for Health Research (NIHR) under its 
Programme Grants for Applied Research program (RP-PG-1210-12005). This study was supported by the NIHR 
Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol 
(BRC-1215-20011). RSC acknowledges support from the NIHR Oxford Biomedical Research Centre. The views 
expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of 
Health and Social Care.  
We thank the following investigators for providing additional information or data on request: Professor Simon P 
Frostick, Department of Molecular and Clinical Cancer Medicine, Cancer Research Centre, 200 London Road, 
Liverpool L3 9TA; Prof Thomas (Quin) Throckmorton, MD, FAAOS, Shoulder and Elbow Surgery, Residency 
Program Director, University of Tennessee-Campbell Clinic, Department of Orthopaedic Surgery; and Armin Arshi, 
MD, Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, 








1. Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. Prosthetic joint infection risk after TKA in the 
Medicare population. Clin Orthop. 2010 Jan;468(1):52-6. PubMed PMID: 19669386. Pubmed Central PMCID: 
2795807. 
2. Blom AW, Taylor AH, Pattison G, Whitehouse S, Bannister GC. Infection after total hip arthroplasty: The 
Avon experience. J Bone Joint Surg Br. 2003 September 1, 2003;85-B(7):956-9. 
3. Moore A, Blom A, Whitehouse M, Gooberman-Hill R. Deep prosthetic joint infection: A qualitative study of 
the impact on patients and their experiences of revision surgery. BMJ open. 2015;5:e009495. 
4. Andersson AE, Bergh I, Karlsson J, Nilsson K. Patients' experiences of acquiring a deep surgical site 
infection: An interview study. Am J Infect Control. 2010;38(9):711-7. 
5. Kunutsor SK, Beswick AD, Peters TJ, Gooberman-Hill R, Whitehouse MR, Blom AW, et al. Health Care 
Needs and Support for Patients Undergoing Treatment for Prosthetic Joint Infection following Hip or Knee 
Arthroplasty: A Systematic Review. PloS one. 2017;12(1):e0169068. PubMed PMID: 28046049. Pubmed Central 
PMCID: PMC5207523. 
6. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the 
United States. J Arthroplasty. 2012 Sep;27(8 Suppl):61-5. PubMed PMID: 22554729. Epub 2012/05/05. eng. 
7. Hunter G, Dandy D. The natural history of the patient with an infected total hip replacement. J Bone Joint 
Surg Br. 1977 August 1, 1977;59-B(3):293-7. 
8. National Joint Registry for England and Wales: 15th Annual Report. Accessed from 
http://www.njrreports.org.uk/Portals/0/PDFdownloads/NJR%2015th%20Annual%20Report%202018.pdf. 2018. 
9. Fehringer EV, Mikuls TR, Michaud KD, Henderson WG, O'Dell JR. Shoulder arthroplasties have fewer 
complications than hip or knee arthroplasties in US veterans. Clin Orthop. 2010 Mar;468(3):717-22. PubMed PMID: 
19626383. Pubmed Central PMCID: PMC2816783. Epub 2009/07/25. 
10. Bonnevialle N, Dauzeres F, Toulemonde J, Elia F, Laffosse JM, Mansat P. Periprosthetic shoulder infection: 
an overview. EFORT Open Rev. 2017 Apr;2(4):104-9. PubMed PMID: 28507783. Pubmed Central PMCID: 
PMC5420823. Epub 2017/05/17. 
11. Abboud JA, Anakwenze OA, Hsu JE. Soft-tissue management in revision total shoulder arthroplasty. J Am 
Acad Orthop Surg. 2013 Jan;21(1):23-31. PubMed PMID: 23281468. Epub 2013/01/03. 
12. Hackett DJ, Jr., Crosby LA. Evaluation and treatment of the infected shoulder arthroplasty. Bull Hosp Jt Dis 
(2013). 2013;71 Suppl 2:88-93. PubMed PMID: 24328588. Epub 2013/12/18. 
13. Bohsali KI, Wirth MA, Rockwood CA, Jr. Complications of total shoulder arthroplasty. J Bone Joint Surg 
Am. 2006 Oct;88(10):2279-92. PubMed PMID: 17015609. Epub 2006/10/04. 
14. Mook WR, Garrigues GE. Diagnosis and Management of Periprosthetic Shoulder Infections. J Bone Joint 
Surg Am. 2014 Jun 4;96(11):956-65. PubMed PMID: 24897745. Epub 2014/06/05. 
15. Morrey BF, Bryan RS. Infection after total elbow arthroplasty. J Bone Joint Surg Am. 1983 Mar;65(3):330-8. 
PubMed PMID: 6826595. Epub 1983/03/01. 
16. Park SE, Kim JY, Cho SW, Rhee SK, Kwon SY. Complications and revision rate compared by type of total 
elbow arthroplasty. J Shoulder Elbow Surg. 2013 Aug;22(8):1121-7. PubMed PMID: 23664747. Epub 2013/05/15. 
17. Kasten MD, Skinner HB. Total elbow arthroplasty. An 18-year experience. Clin Orthop. 1993 May(290):177-




18. Prkic A, Welsink C, The B, van den Bekerom MPJ, Eygendaal D. Why does total elbow arthroplasty fail 
today? A systematic review of recent literature. Arch Orthop Trauma Surg. 2017 Jun;137(6):761-9. PubMed PMID: 
28391430. Epub 2017/04/10. 
19. Kunutsor SK, Whitehouse MR, Blom AW, Beswick AD, INFORM team. Patient-related risk factors for 
periprosthetic joint infection after total joint arthroplasty: A systematic review and meta-analysis. PloS one. 
2016;11(3):e0150866. 
20. Lenguerrand E, Whitehouse MR, Beswick AD, Kunutsor SK, Burston B, Porter M, et al. Risk factors 
associated with revision for prosthetic joint infection after hip replacement: a prospective observational cohort study. 
Lancet Infect Dis. 2018 Jul 25. PubMed PMID: 30056097. Epub 2018/07/30. 
21. Lenguerrand E, Whitehouse MR, Beswick AD, Kunutsor SK, Foguet P, Porter M, et al. Risk factors 
associated with revision for prosthetic joint infection following knee replacement: an observational cohort study from 
England and Wales. Lancet Infect Dis. 2019 Jun;19(6):589-600. PubMed PMID: 31005559. Pubmed Central PMCID: 
PMC6531378. Epub 2019/04/22. 
22. Franceschini V, Chillemi C. Periprosthetic Shoulder Infection. The open orthopaedics journal. 2013;7:243-9. 
PubMed PMID: PMC3731811. 
23. Chand MR, Meiyappan A, Villa JM, Kanwar S, Sabesan VJ, Gilot G. Ninety-Day Readmission Following 
Shoulder Arthroplasty. Journal of Shoulder and Elbow Arthroplasty. 2018;2:2471549218810016. 
24. Deore VT, Griffiths E, Monga P. Shoulder arthroplasty—Past, present and future. Journal of Arthroscopy and 
Joint Surgery. 2018 2018/01/01/;5(1):3-8. 
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of Observational 
Studies in Epidemiology. JAMA: The Journal of the American Medical Association. 2000 April 19, 
2000;283(15):2008-12. Pubmed Central PMCID: 10789670. 
26. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097. PubMed PMID: 19621072. Pubmed Central 
PMCID: 2707599. Epub 2009/07/22. eng. 
27. Barrett MC, Whitehouse MR, Blom AW, Kunutsor SK. Host-related factors for venous thromboembolism 
following total joint replacement: A meta-analysis of 89 observational studies involving over 14 million hip and knee 
replacements. J Orthop Sci. 2019 Apr 24. PubMed PMID: 31029528. Epub 2019/04/29. 
28. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for 
assessing the quality of nonrandomised studies in meta-analyses 2011. 
www.ohri.ca/programs/clinical_epidemiology/oxford.asp. [20 August]. Available from: 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp  
29. Freeman MF, Tukey JW. Transformations Related to the Angular and the Square Root. Ann Math Statist. 
1950 1950/12:607-11. en. 
30. Kunutsor SK, Whitehouse MR, Blom AW, Beswick AD, Inform Team. Re-infection outcomes following one- 
and two-stage surgical revision of infected hip prosthesis: A systematic review and meta-analysis. PloS one. 
2015;10(9):e0139166. 
31. Kunutsor SK, Whitehouse MR, Lenguerrand E, Blom AW, Beswick AD, Inform Team. Re-infection 
outcomes following one- and two-stage surgical revision of infected knee prosthesis: A systematic review and meta-
analysis. PloS one. 2016;11(3):e0151537. 
32. Kunutsor SK, Beswick AD, Whitehouse MR, Wylde V, Blom AW. Debridement, antibiotics and implant 
retention for periprosthetic joint infections: A systematic review and meta-analysis of treatment outcomes. J Infect. 




33. Berstock JR, Beswick AD, Lopez-Lopez JA, Whitehouse MR, Blom AW. Mortality After Total Knee 
Arthroplasty: A Systematic Review of Incidence, Temporal Trends, and Risk Factors. J Bone Joint Surg Am. 2018 
Jun 20;100(12):1064-70. PubMed PMID: 29916935. Epub 2018/06/20. 
34. Cornfield J. A method of estimating comparative rates from clinical data; applications to cancer of the lung, 
breast, and cervix. Journal of the National Cancer Institute. 1951 Jun;11(6):1269-75. PubMed PMID: 14861651. 
35. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177-88. PubMed 
PMID: 3802833. Pubmed Central PMCID: 3802833 
Epub 1986/09/01. eng. 
36. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549. 
PubMed PMID: 21310794. 
37. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc 
Ser A Stat Soc. 2009 Jan;172(1):137-59. PubMed PMID: 19381330. Pubmed Central PMCID: PMC2667312. 
38. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 
1999 Oct 30;18(20):2693-708. PubMed PMID: 10521860. Epub 1999/10/16. eng. 
39. Cook TM, Piatt CJ, Barnes S, Edmiston CE, Jr. The Impact of Supplemental Intraoperative Air 
Decontamination on the Outcome of Total Joint Arthroplasty: A Pilot Analysis. J Arthroplasty. 2019 Mar;34(3):549-
53. PubMed PMID: 30600122. Epub 2019/01/03. 
40. Moeini S, Rasmussen JV, Salomonsson B, Domeij-Arverud E, Fenstad AM, Hole R, et al. Reverse shoulder 
arthroplasty has a higher risk of revision due to infection than anatomical shoulder arthroplasty: 17 730 primary 
shoulder arthroplasties from the Nordic Arthroplasty Register Association. Bone Joint J. 2019 Jun;101-B(6):702-7. 
PubMed PMID: 31154848. Epub 2019/06/04. 
41. Richards J, Inacio MC, Beckett M, Navarro RA, Singh A, Dillon MT, et al. Patient and procedure-specific 
risk factors for deep infection after primary shoulder arthroplasty. Clin Orthop. 2014 Sep;472(9):2809-15. PubMed 
PMID: 24906812. Pubmed Central PMCID: PMC4117904. Epub 2014/06/08. 
42. Cheung EV, Sperling JW, Cofield RH. Infection associated with hematoma formation after shoulder 
arthroplasty. Clin Orthop. 2008 Jun;466(6):1363-7. PubMed PMID: 18421541. Pubmed Central PMCID: 
PMC2384030. Epub 2008/04/19. 
43. Drake GN, O'Connor DP, Edwards TB. Indications for reverse total shoulder arthroplasty in rotator cuff 
disease. Clin Orthop. 2010 Jun;468(6):1526-33. PubMed PMID: 20049573. Pubmed Central PMCID: PMC2865601. 
Epub 2010/01/06. 
44. Wang CA, Palmer JR, Madden MO, Cohen-Levy W, Vakharia RM, Roche MW. Perioperative complications 
in patients with sleep apnea following primary total shoulder arthroplasty: An analysis of 33,366 patients. J Orthop. 
2019 Sep-Oct;16(5):382-5. PubMed PMID: 31110398. Pubmed Central PMCID: PMC6512835. Epub 2019/05/22. 
45. Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive 
sleep apnea: implications for treatment. Chest. 2010 Mar;137(3):711-9. PubMed PMID: 20202954. Pubmed Central 
PMCID: PMC3021364. Epub 2010/03/06. 
46. Voloshin I, Schippert DW, Kakar S, Kaye EK, Morrey BF. Complications of total elbow replacement: a 
systematic review. J Shoulder Elbow Surg. 2011 Jan;20(1):158-68. PubMed PMID: 21134667. Epub 2010/12/08. 
47. Welsink CL, Lambers KTA, van Deurzen DFP, Eygendaal D, van den Bekerom MPJ. Total Elbow 
Arthroplasty: A Systematic Review. JBJS Rev. 2017 Jul;5(7):e4. PubMed PMID: 28696952. Epub 2017/07/12. 
48. van der Lugt JC, Rozing PM. Systematic review of primary total elbow prostheses used for the rheumatoid 




49. Padegimas EM, Maltenfort M, Ramsey ML, Williams GR, Parvizi J, Namdari S. Periprosthetic shoulder 
infection in the United States: incidence and economic burden. J Shoulder Elbow Surg. 2015 5//;24(5):741-6. 
50. Rhee YG, Cho NS, Park JG, Song JH. Resection arthroplasty for periprosthetic infection after total elbow 
arthroplasty. J Shoulder Elbow Surg. 2016 Jan;25(1):105-11. PubMed PMID: 26475639. Epub 2015/10/18. 
51. Wagner ER, Ransom JE, Kremers HM, Morrey M, Sanchez-Sotelo J. Comparison of the hospital costs for 
two-stage reimplantation for deep infection, single-stage revision and primary total elbow arthroplasty. Shoulder 
Elbow. 2017 Oct;9(4):279-84. PubMed PMID: 28932285. Pubmed Central PMCID: PMC5598824. Epub 2017/09/22. 
52. Gundtoft PH, Overgaard S, Schonheyder HC, Moller JK, Kjaersgaard-Andersen P, Pedersen AB. The "true" 
incidence of surgically treated deep prosthetic joint infection after 32,896 primary total hip arthroplasties. Acta 








Figure 1. PRISMA flow diagram 
244 Potentially relevant citations identified
From MEDLINE, Embase, Web of Science, 
Cochrane Library, and reference list of 
relevant studies
91 excluded on the basis of title 
and/ or abstract
48 Articles excluded due to:
21 Population not relevant
14 Duplicate of another study
9 Outcome not relevant
3 Study design not relevant
1 Full text not retrievable
105 Articles included, based on 108 
unique studies




































Figure 2. Incidence rates of infection following primary TSR across eligible studies 
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The summary incidence rate estimate presented was calculated using random effects models; CI, confidence interval 
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A, Incidence of TSR PJI by median year of data collection; B, Meta-regression bubble plot of incidence of TSR PJI 
against median year of study data collection; C, Incidence of TER PJI by median year of data collection; D, Meta-
regression bubble plot of incidence of TER PJI against median year of study data collection; capped vertical bars 







Figure 4. Incidence rates of infection following primary TER across eligible studies 
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The summary incidence rate estimate presented was calculated using random effects models; CI, confidence interval 






Figure 5. Sociodemographic characteristics, body mass index comparisons, medical and surgical history 
characteristics and risk of PJI following primary TSR 
Age
≥75 years vs <75 years
≥55 years vs <55 years






Current smoking vs None
Body mass index
BMI ≥30 vs <30 kg/m2
BMI ≥25 vs <25 kg/m2
Per unit increase in BMI kg/m2
Comorbidity
Diabetes vs None
Sleep apnoea vs None
Comorbidity index
ASA grade 3/4 vs 1/2
Surgical history
Previous shoulder surgery vs None
Indication for TSR
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ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval (bars); IA, inflammatory 







Figure 6. Surgery- and hospital-related factors and risk of PJI following primary TSR 
TSR procedure
Reverse TSR vs Anatomic TSR
Length of stay
Outpatient TSR vs Inpatient TSR
Implant fixation
Cement vs No cement
Surgeon experience
Residents/Fellows vs  None
Period of surgery






































Table 1. Summary characteristics of the 109 unique studies 
 
Characteristics 
Total shoulder replacement 
(24 studies) 
Total elbow replacement 
(85 studies) 
Population N  N  
Participants/procedures 627,326 17,485 
Prosthetic joint infection 1,751 525 
Superficial wound infection 16 19 
Study characteristics   
Location N studies (N participants/procedures) N studies (N participants/procedures) 
    North America 18 (613,434) 20 (10,773) 
    Europe 5 (18,380) 51 (5,795) 
    Asia 1 (40) 12 (889) 
    Pacific - 1 (28) 
Study design N studies (N participants/procedures) N studies (N participants/procedures) 
    Retrospective cohorts 19 (608,980) 72 (14,212) 
    Prospective cohorts 5 (22,874) 12 (3,273) 
Weighted mean follow-up (min-max), years 1.27 (0.01-20.00) 3.31 (0.08-18.00) 
Median (IQR) study quality score for observational studies 8 (7-9) 7 (6-7) 
Study level participant characteristics   
Weighted mean age (min-max), years 68.8 (66.0-72.7) 59.5 (28.0-70.0) 
Median (IQR) % males 43.6 (36.7-45.0) 22.6 (16.7-293) 
   
 










Supplementary Material 1 PRISMA checklist 
Supplementary Material 2 MOOSE checklist 
Supplementary Material 3 Literature search strategy 
Supplementary Material 4 Reference list of 106 included articles 
Supplementary Material 5 Characteristics of studies included in review 
Supplementary Material 6 Incidence rate of PJI by TSR procedure type 
Supplementary Material 7 Incidence of PJI following primary TSR at specific average follow-up periods 
Supplementary Material 8 Incidence rate of PJI by TER prosthesis type 
Supplementary Material 9 Incidence of PJI following primary TER at specific average follow-up periods 









No Checklist item Reported on page No 
Title 




2 Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility 
criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and 
implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Introduction 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, 




6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years 




7 Describe all information sources (such as databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched 
Methods 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated 
Supplementary Material 3 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if 




10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions 
and simplifications made 
Methods 
Risk of bias in 
individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 




13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of 
results 
14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (such as I2 statistic) for each meta-analysis 
Methods 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, 




16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified 
Methods 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram 
Results, Figure 1 
Study 
characteristics 
18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up 
period) and provide the citations 
Results, Table 1, 
Supplementary Material 5 
Risk of bias 
within studies 





20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each 
intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
Results, Figures 2-6 
Synthesis of 
results 
21 Present results of each meta-analysis done, including confidence intervals and measures of consistency Results, Figures 2-6; 
Supplementary Materials 
6-10 
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable 
Additional 
analysis 






24 Summarise the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (such as health care providers, users, and policy makers) 
Discussion 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete 
retrieval of identified research, reporting bias) 
Discussion 




Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role of 





Supplementary Material 2. MOOSE checklist  
 
Prosthetic joint infection following 649,376 primary total shoulder and elbow replacements: meta-analyses of 
incidence rates, temporal trends and potential risk factors  
 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
 Problem definition Data on incidence rates of prosthetic joint infection (PJI) following upper 
extremity joint replacement is variable. Whether risk factors for PJI 
following hip and knee replacements influence the risk for PJI following 
upper extremity joint replacement in a similar manner is uncertain. We 
conducted a systematic meta-analysis to evaluate the incidence and its 
temporal trends as well as potential risk factors for PJI following primary 
total shoulder replacement (TSR) and elbow replacement (TER). 
 Hypothesis statement Several patient-, surgery-, implant-, and hospital-related factors influence the 
risk of PJI following primary TSR or TER 
 Description of study outcomes PJI and superficial wound infection 
 Type of exposure  Patient-, surgery-, implant-, and hospital-related factors 
 Type of study designs used Longitudinal studies (prospective or retrospective case control, prospective 
cohort, retrospective cohort, case-cohort, nested-case control, or clinical 
trials) 
 Study population Patients followed for PJI following primary TSR or TER 
Reporting of search strategy should include  
 Qualifications of searchers  
 Search strategy, including time period 
included in the synthesis and keywords 
Time period: from inception to June 2019  
The detailed search strategy can be found in Supplementary Material 3 
 Databases and registries searched MEDLINE, EMBASE, and Cochrane databases 
 Search software used, name and version, 
including special features 
OvidSP was used to search EMBASE and MEDLINE 
EndNote used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  The 
citation list for excluded studies are available on request. 
 Method of addressing articles published 
in languages other than English 
Not applicable 
 Method of handling abstracts and 
unpublished studies 
Abstracts with no full text publications were not included. 
 Description of any contact with authors We contacted authors of studies that did not provide adequate data in their 
studies 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled for 
assessing the hypothesis to be tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
 Rationale for the selection and coding of 
data 
Data extracted from each of the studies were relevant to the population 
characteristics, study design, exposure, and outcome. 
 Assessment of confounding We assessed confounding by ranking individual studies on the basis of 
different adjustment levels and performed sub-group analyses to evaluate 
differences in the overall estimates according to levels of adjustment. 
 Assessment of study quality, including 
blinding of quality assessors; 
stratification or regression on possible 
predictors of study results 
Study quality was assessed based on the nine-star Newcastle–Ottawa Scale 
using pre-defined criteria namely: population representativeness, 
comparability (adjustment of confounders), ascertainment of outcome.  
 Assessment of heterogeneity Heterogeneity of the studies was quantified with I2 statistic that provides the 
relative amount of variance of the summary effect due to the between-study 
heterogeneity and explored using meta-regression and stratified analyses 
 Description of statistical methods in 
sufficient detail to be replicated 
Description of methods of meta-analyses, sensitivity analyses, and meta-
regression are detailed in the methods. We performed random effects meta-
analysis with Stata 15. 
 Provision of appropriate tables and 
graphics 
Table 1; Figures 1-6; Supplementary Materials 1-10 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 




 Table giving descriptive information for 
each study included 
Supplementary Material 5 
 Results of sensitivity testing 
 
Not applicable  
 Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates, I2 
values and results of sensitivity analyses 
Reporting of discussion should include  
 Quantitative assessment of bias Sensitivity analyses indicate heterogeneity in strengths of the association due 
to most common biases in observational studies.  The systematic review is 
limited in scope, as it involves published data. Individual participant data is 
needed. Limitations have been discussed. 
 
 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria in 
methods section. 
 Assessment of quality of included studies Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
 Consideration of alternative explanations 
for observed results 
Discussion 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research We recommend analyses of individual participant data 





Supplementary Material 3. Literature search strategy 
Relevant studies, published from inception to 20 June 2019 (date last searched), were identified through electronic searches limited to the 
English language using MEDLINE, Embase, Web of Science, and Cochrane databases. Electronic searches were supplemented by scanning 
reference lists of articles identified for all relevant studies (including review articles), by hand searching of relevant journals and by 
correspondence with study investigators.  
1     exp Arthroplasty, Replacement, Shoulder/ (761) 
2     exp Arthroplasty, Replacement, Elbow/ (349) 
3     periprosthetic joint infection.mp. (1171) 
4     prosthetic joint infection.mp. (1173) 
5     prosthetic infection.mp. (415) 
6     exp Wound Infection/ (45091) 
7     deep infection.mp. (2901) 
8     exp Surgical Wound Infection/ (34798) 
9     1 or 2 (1107) 
10     3 or 4 or 5 or 6 or 7 or 8 (49918) 
11     9 and 10 (64) 
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Supplementary Material 5. Characteristics of studies included in review 
 
Author, year of 
publication 
Country Year of study Type of implant Study design Mean/median 
age (years) 














Singh, 2012 USA 1976-2008 NR Prospective cohort 65.0 47.0 7.0 2588 32 Deep prosthetic 
infection (Surgeon 
reported) 




Berth, 2013 Germany 2006-2009 NR Prospective cohort 67.0 34.1 2.7 82 1 Superficial wound 
infection (NR) 
NR 8 




(27.5%); CN S. aureus 
(13.7) 
9 
Chalmers, 2014 USA 
 
NR Retrospective cohort 66.3 42.0 > 90 days 127 0 Infection (NR) NA 8 
Griffin, 2014b USA 1998-2008 NR Retrospective cohort 68.8 44.0 2.57 days 31924 32 Infection (NR) NR 7 
Caceres-Sanchez, 2015 Spain 2004-2012 NR Retrospective cohort 70.2 16.0 3.0 52 2 Deep infection (NR) NR 7 
Churchill, 2016 USA 2011-2012 Simpliciti canal-
sparing 
Prospective cohort 66.0 71.3 2.0 157 1 Infection (NR) NR 8 
Leschinger, 2016 Germany 1998-2009 Aequalis Total 
Shoulder 
Prospective cohort 68.0 27.6 3.6 275 3 Infection (NR) NR 9 
Leroux, 2016 USA 2005-2014 NR Retrospective cohort NR 51.3 30 days 7197 48 Infection (NR) NR 7 
Villacis, 2016 USA 2011-2013 NR Retrospective cohort 70.1 45.0 2.0 10844 140 Infection (NR) NR 6 
Anakwenze, 2017 USA 2007-2013 NR Prospective cohort 70.1 47.4 2.6 4630 36 Deep SSI (NR) NR 9 
Basques, 2017 USA 2005-2012 NR Retrospective cohort NR 38.4 90 days 123347 633 SSI (NR) NR 8 
Cho, 2017 Korea 2010-2015 NR Retrospective cohort 72.7 17.5 2.2 40 1 Deep infection (NR) NR 6 
Everhart, 2017 USA 2000-2011 NR Retrospective cohort NR NR 30 days 485 16 SSI (Surgeon reported) Cutibacterium acnes 
(42.9%) 
8 
Johansson, 2017 Sweden 2008-2012 NR Retrospective cohort NR 45.2 2.0 241 11 PJI (Microbiology) Cutibacterium acnes 
(72.7%) 
9 
Rao, 2017 USA 2005-2012 NR Retrospective cohort NR NR 30 days 1591 2 Deep infection (NR) NR 8 
Wagner, 2017 USA 1970-2013 NR Retrospective cohort 68.0 45.0 10.0 4567 48 Deep infection (NR) NR 9 
Wagner, 2017b USA 1970-2012 NR Retrospective cohort 67.0 45.0 20.0 5494 83 PJI (NR) NR 8 
Werthel, 2017b USA 1970-2012 NR Retrospective cohort 66.2 45.0 6.8-7.4 4577 68 PJI (Surgeon reported) NR 9 
Arshi, 2018 USA 2007-2016 NR Retrospective cohort 70-74 40.3 1.0 17542 118 Infection (NR) NR 8 
Chand, 2018 USA 2010-2016 NR Retrospective cohort 71.7 46.7 90 days 184 4 SSI (NR) NR 6 
Nelson, 2018 USA 2009-2012 NR Retrospective cohort NR NR 5.0 80 1 Deep infection (NR) NR 7 
Saltzman, 2018 USA 2002-2011 NR Retrospective cohort 66-70.8 40.3 NR 372753 373 SSI (NR) NR 8 
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Scott, 2019 USA 2014 NR Retrospective cohort 72.3 36.7 90 days 25196 45 Infection (NR) NR 8 
Cook, 2019 USA 2016-2017 NR Retrospective cohort NR NR 1.0 24 0 PJI (MSIS criteria) NA 7 
Walters, 2019 USA 2009-2014 NR Retrospective cohort 67.0 52.0 3.0 102 3 PJI (NR) NR 6 
Wang, 2019 USA 2005-2014 NR Retrospective cohort NR 48.9 2.0 33366 726 PJI (NR) NR 7 
Moeini, 2019 Denmark 2004-2013 NR Prospective cohort NR 30.4 3.8 17730 188 Revision for PJI 
(Surgeon reported) 
NR 9 
Yin, 2019 USA 2006-2015 NR Retrospective cohort 63.9 39 30 days 2785 10 Deep SSI (NR) NR 8 
TER 
Weiland, 1989 USA 1976-1984 Capitellocondylar 
TER 
Retrospective cohort 56.0 28.6 7.2 45 2 Deep infection (NR) NR 7 
Wolfe, 1990 USA 1974-1986 NR Retrospective cohort 18-78 32.0 6.0 164 12 Deep infection 
(Culture findings) 
S. aureus (75%) 7 
Ruth, 1992 USA 1976-1986 Capitellocondylar 
TER 
Retrospective cohort 56.0 12.2 6.5 51 4 Infection (NR) CNSA (50%) 7 
Morrey, 1992 USA 1982-1988 Coonrad/Morrey Total 
Elbow 
Retrospective cohort NR NR 3.8 68 4 Infection (NR) NR 7 
Ewald, 1993 USA 1974-1987 Capitellocondylar 
TER 
Retrospective cohort NR NR 5.8 312 7 Deep infection (NR) NR 7 
Ewald, 1993 USA 1974-1987 Capitellocondylar 
TER 
Retrospective cohort NR NR 5.8 312 2 Superficial wound 
infection (NR) 
NR 7 
Kasten, 1993 USA 1974-1988 NR Retrospective cohort NR NR 7.6 34 4 Infection (NR) NR 7 
Alnot, 1994 France 1986-1991 Guepar Retrospective cohort 58.0 16.1 2.7 33 2 Deep infection (NR) NR 6 
Lyall, 1994 UK 1987-1990 Souter-Strathclyde Retrospective cohort 60.0 23.5 3.4 19 0 Infection (NR) NA 7 
Kraay, 1994 USA 1983-1989 Semiconstrained 
prosthesis 
Retrospective cohort 53.0 76.8 8.3 113 7 Deep infection (NR) NR 7 
Ljung, 1995 Sweden 1989-1993 Capitellocondylar 
TER 
Prospective cohort 62.0 9.5 1.0 50 1 Infection (NR) NR 5 
Sjoden, 1995 Sweden 1982-1992 Souter-Strathclyde Prospective cohort 62.0 16.7 5.0 19 0 Infection (NR) NA 6 
Risung, 1997 Norway 1987-1996 Norway Elbow Prospective cohort 62.1 NR 4.3 118 2 Deep infection (NR) NR 7 
Allieu, 1998 France 1983-1989 Roper-Tuke Retrospective cohort 52.8 NR 9.5 21 1 Infection (NR) NR 7 
Verstreken, 1998 Belgium 1991-1996 Kudo  Prospective cohort 56.0 26.7 3.0 16 1 Deep infection (NR) NR 7 
Gschwend, 1999 Switzerland 1978-1986 GSB III prosthesis Retrospective cohort NR NR 13.5 59 3 Deep infection (NR) NR 6 
Kudo, 1999 Japan 1993-1999 Kudo type-5 Prospective cohort 55.0 13.5 3.8 43 0 Infection (NR) NA 7 
Schneeberger, 2000 Switzerland 1988-1995 GSB III prosthesis Retrospective cohort 57.6 28.6 6.0 14 1 Infection (NR) Streptococcus 
Pneumoniae 
7 
Hildebrand, 2000 Canada 1989-1996 Coonrad/Morrey Total 
Elbow 
Retrospective cohort 64.0 28.6 4.2 51 3 PJI (NR) NR 6 
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Wright, 2000 USA 1985-1997 Mayo-Coonrad Retrospective cohort 62.8 42.9 3.0 14 0 Infection (NR) NA 7 
Wright, 2000 USA 1985-1997 Ewald Retrospective cohort 63.1 16.7 6.1 12 1 Infection (NR) Acinetobacter 7 
Dainton, 2002 UK 1987-1996 Souter-Strathclyde Retrospective cohort 59.0 16.7 6.0 44 1 Deep infection (NR) NR 6 
Ikävalko, 2002 Finland 1982-1997 Souter-Strathclyde Retrospective cohort 57.0 8.4 15.0 525 12 Deep infection (NR) NR 7 
Ikävalko, 2002 Finland 1982-1997 Souter-Strathclyde Retrospective cohort 57.0 8.4 15.0 525 3 Superficial wound 
infection (NR) 
NR 7 
Rahme, 2002 Sweden 1992-1998 Kudo  Retrospective cohort 63.0 21.4 5.0 30 2 Deep infection (NR) NR 7 
Mansat, 2003 France 1988-1996 Guepar Retrospective cohort 58.0 6.3 5.6 19 1 Deep infection (NR) NR 6 
Mansat, 2003 France 1988-1996 Guepar Retrospective cohort 58.0 6.3 5.6 19 1 Superficial wound 
infection (NR) 
NR 6 
Lo, 2003 China 1992-2002 Coonrad/Morrey Total 
Elbow 
Retrospective cohort 58.0 NR 3.0 23 1 Deep infection (NR) MRSA 7 
Espag, 2003 UK 1991-2000 Souter-Strathclyde Retrospective cohort NR NR 5.7 11 0 Deep infection (NR) NA 7 
Espag, 2003 UK 1991-2000 Souter-Strathclyde Retrospective cohort NR NR 5.7 11 2 Superficial wound 
infection (NR) 
NR 7 
Potter, 2003 UK 1993-1996 Kudo type-5 Retrospective cohort 60.0 NR 6.0 35 0 Infection (NR) NA 5 
Reinhard, 2003 Netherlands 1990-1997 Kudo type-4 Retrospective cohort 53.0 NR 7.0 57 1 Superficial wound 
infection (NR) 
NR 7 
Kelly, 2004 Australia 1988-1995 GSB III prosthesis Retrospective cohort NR 4.3 7.6 28 1 Deep infection (NR) NR 6 
Kelly, 2004 Australia 1988-1995 GSB III prosthesis Retrospective cohort NR 4.3 7.6 28 2 Superficial wound 
infection (NR) 
NR 6 
Willems, 2004 Belgium 1991-2002 Kudo  Retrospective cohort 57.5 34.3 4.8 36 1 Deep infection (NR) NR 7 
Ovesen, 2005 Denmark 1994-2000 Capitellocondylar 
TER 
Retrospective cohort 56.4 29.3 6.9 51 3 Deep infection (NR) NR 7 
Little, 2005 UK 1992-1998 Souter-Strathclyde Retrospective cohort 63.0 18.2 5.1 33 1 Infection (NR) NR 7 
Little, 2005 UK 1993-1997 Kudo  Retrospective cohort 60.0 33.3 5.6 33 0 Infection (NR) NA 7 
Little, 2005 UK 1997-1999 Coonrad/Morrey Total 
Elbow 
Retrospective cohort 65.0 24.2 5.7 33 2 Infection (NR) NR 7 
Khatri, 2005 UK 1991-1996 Souter-Strathclyde Retrospective cohort 61.0 19.1 6.8 47 3 Deep infection (NR) S. epidermidis (33.3%) 7 
van der Lugt, 2005 Netherlands 1982-2000 Souter-Strathclyde Prospective cohort NR NR 6.4 204 10 Infection (NR) NR 6 
Landor, 2006 Czech 1988-2000 Souter-Strathclyde Retrospective cohort 53.0 14.3 9.5 58 1 Deep infection (NR) NR 7 
Jensen, 2006 Denmark 1990-1997 GSB III prosthesis Retrospective cohort NR 15.8 5.0 23 0 Infection (NR) NA 6 
Rauhaniemi, 2006 Finland 1997-2001 Kudo type-5 Retrospective cohort 58.0 18.5 4.8 28 0 Infection (NR) NA 7 
Thillemann, 2006 Denmark 1992-1993 Kudo type-3 Retrospective cohort 60.3 18.8 9.5 17 1 Deep infection (NR) NR 7 
Bassi, 2007 UK 2000-2002 Acclaim Prospective cohort 64.0 25.0 3.0 36 1 Deep infection (NR) NR 6 
Schmidt, 2007 Germany 1987-2005 Mixture of several 
prosthesis 
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Cesar, 2007 France 1993-2002 GSB III prosthesis Retrospective cohort 55.7 NR 6.2 58 0 Deep infection (NR) NA 7 
Shi, 2007 USA 1990-2003 Coonrad/Morrey Total 
Elbow 
Retrospective cohort 61.0 24 7.2 37 3 Infection (NR) NR 9 
Tachira, 2008 Japan 1998-2006 J-alumina ceramic 
elbow 
Retrospective cohort 59.7 NR 4.6 3 1 Deep infection (NR) Enterobacter cloacae 6 
Tachira, 2008 Japan 1998-2006 STABLE Retrospective cohort 60.6 NR 5.0 13 0 Deep infection (NR) NA 6 
Tachira, 2008 Japan 1998-2006 Kudo Retrospective cohort 62.7 NR 2.4 32 2 Deep infection (NR) S. aureus; Pseudomonas 
aeruginosa 
6 
Hilker, 2009 Germany 1987-2005 Mixture of several 
prosthesis 
Retrospective cohort 63.5 15.3 5.5 195 21 Deep infection (NR) NR 7 
Hilker, 2009 Germany 1987-2005 Mixture of several 
prosthesis 
Retrospective cohort 63.5 15.3 5.5 195 1 Superficial wound 
infection (NR) 
NR 7 
Celli, 2009 USA 1982-2003 Coonrad/Morrey Total 
Elbow 
Retrospective cohort 32.0 22.4 7.6 55 2 Deep infection (NR) NR 7 
Patil, 2009 USA 1994-2001 Solar Total Elbow Retrospective cohort 63.4 NR 8.4 17 1 Deep infection (NR) NR 7 
Amirfeyz, 2009 UK 1996-2004 GSB III prosthesis Retrospective cohort 69.0 24.4 4.5 54 0 Deep infection (NR) NA 7 
Skytta, 2009 Finland 1982-2006 Mixture Prospective cohort 59.0 13.0 7.5 1457 25 Revision for PJI 
(Surgeon reported) 
NR 9 
Naqui, 2010 UK 2000-2006 Acclaim Retrospective cohort 65.4 72.7 4.8 13 0 Deep infection (NR) NA 7 
Corradi, 2010 Italy 2000-2007 Coonrad/Morrey Total 
Elbow 
Retrospective cohort 69.0 NR 5.0 18 1 Superficial wound 
infection (NR) 
NR 7 
Prasad, 2010 UK 1993-2000 Souter-Strathclyde Retrospective cohort 60.0 20.0 9.0 44 1 Infection (NR) NR 6 
Prasad, 2010 UK 1997-2010 Coonrad/Morrey  Retrospective cohort 62.0 33.3 5.0 55 1 Infection (NR) NR 6 
Qureshi, 2010 UK 1993-1996 Kudo-5 Retrospective cohort 56.0 NR 11.9 34 2 Infection (NR) NR 6 
Guttler, 2011 Czech 1988-2000 Souter-Strathclyde Retrospective cohort 53.0 NR 9.5 58 1 Deep infection (NR) NR 6 
Guttler, 2011 Czech 2000-2009 Coonrad/Morrey Total 
Elbow 
Retrospective cohort 54.0 NR 4.21 63 2 Deep infection (NR) NR 6 
Sorbie, 2011 Canada 1995-2002 Sorbie-QUESTOR Retrospective cohort 51.0 50.0 7.5 51 7 Infection (NR) NR 7 
Gay, 2012 USA 1997-2006 NR Retrospective cohort 58.3 28.8 90 days 1155 36 Infection (NR) NR 7 
Ishii, 2012 Japan 2001-2009 GSB III prosthesis Retrospective cohort 66.0 0.0 6.3 36 0 Deep infection (NR) NA 7 
Maheshwari, 2012 UK NR Coonrad/Morrey Total 
Elbow 
Retrospective cohort 65.0 32.1 4.6 31 1 Deep infection (NR) NR 7 
Park, 2013 Korea 1984-2010 Pritchard ERS; Kudo Retrospective cohort 53.0 20.0 8.0 35 1 Infection (NR) NR 7 
Park, 2013 Korea 1984-2010 Pritchard Mark II; 
Coonrad-Morrey 
Retrospective cohort 61.0 38.8 14.0 49 0 Infection (NR) NA 7 
Kodde, 2013 Belgium 2006-2011 Coonrad/Morrey Total 
Elbow 
Prospective cohort 70.0 23.5 2.7 17 1 Infection (NR) NR 6 
Kodde, 2013 Belgium 2006-2011 Coonrad/Morrey Total 
Elbow 
Prospective cohort 70.0 23.5 2.7 17 1 Superficial wound 
infection (NR) 
NR 6 
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Baghdadi, 2014 USA 1987-2006 Coonrad/Morrey Total 
Elbow 
Retrospective cohort 62.3 24.0 5.8 723 20 Revision for deep 
infection (NR) 
NR 8 
Cross, 2014 USA 1988-1995 Osteonics Total Elbow Retrospective cohort 28.0 30.0 18.0 10 1 Deep infection (NR) NR 6 
Hastings, 2014 USA 2002-2009 Discovery Elbow 
System 
Prospective cohort 63.9 22.8 4.1 92 2 Deep infection (NR) NR 7 
Hastings, 2014 USA 2002-2009 Discovery Elbow 
System 
Prospective cohort 63.9 22.8 4.1 92 2 Superficial wound 
infection (NR) 
NR 7 
Large, 2014 UK 2008-2011 Discovery Elbow 
System 
Retrospective cohort 69.2 37.0 3.4 51 4 PJI (NR) NR 7 




Retrospective cohort 62.0 19.2 8.7 172 2 Revision for infection NR 7 
Plaschke, 2014 Denmark 1990-2008 Coonrad-Morrey, GSB 
III, Discovery 
Retrospective cohort 64.0 17.8 8.7 152 3 Revision for infection NR 7 
Alizadehkhaiyat, 2015 UK 2003-2010 Discovery Elbow 
System 
Prospective cohort NR NR 4.0 75 1 Deep infection (NR) NR 7 
Kiran, 2015 UK NR Coonrad/Morrey Total 
Elbow 
Retrospective cohort 67.3 34.0 8.1 50 2 Deep infection (NR) NR 9 
Kiran, 2015 UK NR Coonrad/Morrey Total 
Elbow 
Retrospective cohort 67.3 34.0 8.1 50 3 Superficial wound 
infection (NR) 
NR 9 
Griffin, 2015 USA 2005-2011 NR Retrospective cohort <65->80 18.6 90 days 7580 218 Infection (NR) NR 7 
Williams, 2016 UK 2000-2012 Coonrad/Morrey Total 
Elbow 
Retrospective cohort 59.1 42.9 5.3 22 1 Deep infection (NR) NR 6 
Toulemonde, 2016 France 1997-2008 Coonrad/Morrey  Retrospective cohort 63.0 18.7 5.0 100 4 Deep infection (NR) NR 7 
Kodama, 2017 Japan 1994-2003 Kudo type-5 Retrospective cohort 58.9 3.2 11.8 41 1 Deep infection (NR) NR 9 
Lovy, 2017 USA 2007-2013 NR Retrospective cohort 63.3 25.0 30 days 189 3 Deep infection (NR) NR 7 
Nishida, 2018 Japan 2003-2012 J-alumina ceramic 
elbow 
Retrospective cohort 62.0 4.0 9.0 87 1 Deep infection (NR) NR 7 
Minami, 2018 Japan 1982-2007 Kudo Retrospective cohort 56.6 17.6 12.3 421 8 Deep infection (NR) MRSA (37.5%); S. 
aureus (25%) 
6 
Kondo, 2019 Japan 1998-2014 Niigata- Senami-
Kyocera modular 
system 





CDC, Center for Disease Control; CNSA, Coagulase Negative Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; MSIS, Musculoskeletal Infection Society; NHSN, 








Supplementary Material 6. Incidence rate of PJI by TSR procedure type 
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Supplementary Material 8. Incidence rate of PJI by TER prosthesis type 
 
.       (0.95, 4.18)












































































































































































































































































































































































BMI ≥30 vs <30 kg/m2
BMI ≥40 vs <40 kg/m2
Comorbidity
Psychiatric illness vs None
Surgical history
Previous elbow surgery vs None
Indication for TER
































BMI, body mass index; CI, confidence interval; PJI, prosthetic joint infection; RR, relative risk; TER, total elbow 
replacement 
 
 
 
